Neuropeptide Y, peptide YY and pancreatic polypeptide belong to a related research family, but the family heading does not identify an experimental ligand. Even NPY itself can appear as an intact molecule or a shorter processed form. Its discovery and processing studies show why a precise form name is needed before discussing receptor selectivity.
Read the species attached to the sequence
Tatemoto’s 1982 sequence paper identified a 36-residue peptide from porcine brain, ending in amidated tyrosine. Its relationship to peptide YY and pancreatic polypeptide helped establish a peptide family.Tatemoto — Complete amino-acid sequence of porcine NPY (opens in a new tab)
The IUPHAR/BPS human NPY structure record also specifies 36 residues and an amidated terminal tyrosine. Comparing its sequence with the original porcine sequence shows methionine at position 17 in the human reference where the porcine sequence has leucine.IUPHAR/BPS — Human neuropeptide Y structure (opens in a new tab)Tatemoto — Complete amino-acid sequence of porcine NPY (opens in a new tab)
| Field | Detail to preserve |
|---|---|
| Species | The ligand sequence, not only the experimental animal |
| Residue interval | For example, intact 1–36 or truncated 3–36 |
| Terminal chemistry | The reference carboxyl-terminal amide |
| Family member | NPY, PYY and pancreatic polypeptide separately |
A family relationship helps locate relevant comparisons. It is not evidence that an experiment on PYY used NPY, or that all species-labelled sequences are chemically identical.
Removal of Tyr–Pro creates a different molecular form
Mentlein and colleagues’ 1993 study found that purified human dipeptidyl peptidase IV removed the amino-terminal Tyr–Pro pair from NPY. Related cleavage was observed in human-serum and cultured-endothelial-cell experiments, supporting a possible processing role for the enzyme.Mentlein and colleagues — NPY/PYY processing by dipeptidyl peptidase IV (opens in a new tab)
The product retains residues 3 through 36: 34 residues when both endpoints are counted. The number 36 still identifies the original endpoint; it does not state the length of the shortened molecule.
This processing question is different from asking whether total NPY-related material increases or decreases. Parent and product can change in opposite directions while a broad assay reports little net difference.
What the direct binding comparison established
Grandt and colleagues’ 1996 study identified endogenous NPY(3–36) in porcine brain and compared it with intact NPY in two cell models. The shorter form retained high affinity at Y2-like sites but had markedly lower affinity at Y1-like sites.Grandt and colleagues — Endogenous NPY(3–36) and Y2 selectivity (opens in a new tab)
The reported Y1-like comparison used SK-N-MC cells, while the Y2-like comparison used CHP234 cells. These defined models support a selectivity interpretation without representing every receptor subtype or tissue.Grandt and colleagues — Endogenous NPY(3–36) and Y2 selectivity (opens in a new tab)
The important point is the pattern across the two measurements. A fragment that binds one tested target less well while retaining binding at another has changed selectivity, rather than simply losing all biological relevance.
Binding remains a molecular interaction measurement. Its conversion into secretion, firing, feeding or another functional outcome requires the relevant downstream experiment.
Avoid assigning a family-wide effect to a single ligand
When assembling an NPY reading list, place the molecular form in the first column and the receptor or cell system in the second. This prevents intact NPY, its fragments and other Y-family ligands from becoming one undifferentiated evidence pool.
Keep the original species where it matters. The early porcine isolation establishes that molecule in that tissue; a human sequence record answers a different identity question.
For any claim about appetite, stress or metabolism, ask whether the paper measured that outcome directly and whether the intervention matches the named form. Receptor preference alone cannot specify the size or direction of a whole-organism effect.
This reference provides a way to interpret the molecular literature. It does not recommend NPY administration or imply that a peptide-family association establishes a benefit from an unspecified preparation.
Sources and further detail
- Tatemoto — Complete amino-acid sequence of porcine NPY (opens in a new tab)
Original 1982 abstract and printed sequence read, retaining porcine origin, residue 17 and terminal amidation.
- IUPHAR/BPS — Human neuropeptide Y structure (opens in a new tab)
Curated sequence and terminal-modification fields read. Species comparison made explicitly against the original porcine sequence.
- Mentlein and colleagues — NPY/PYY processing by dipeptidyl peptidase IV (opens in a new tab)
Original 1993 publisher abstract read and authorship checked. Purified enzyme, serum and cultured-cell observations distinguished from an in-vivo flux measurement.
- Grandt and colleagues — Endogenous NPY(3–36) and Y2 selectivity (opens in a new tab)
Complete original 1996 abstract read. Porcine discovery and the two named cell-binding models retained without whole-organism efficacy extrapolation.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.